14,285 Shares in AxoGen, Inc. (NASDAQ:AXGN) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 14,285 shares of the medical equipment provider’s stock, valued at approximately $235,000.

Several other institutional investors have also recently bought and sold shares of AXGN. Quest Partners LLC grew its position in shares of AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the last quarter. R Squared Ltd acquired a new stake in AxoGen in the 4th quarter valued at approximately $30,000. Oppenheimer & Co. Inc. bought a new position in AxoGen in the 3rd quarter worth approximately $156,000. Quantbot Technologies LP acquired a new position in shares of AxoGen during the third quarter worth approximately $165,000. Finally, BNP Paribas Financial Markets boosted its position in shares of AxoGen by 238.6% in the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider’s stock valued at $172,000 after acquiring an additional 8,656 shares during the period. Institutional investors own 80.29% of the company’s stock.

AxoGen Trading Down 3.5 %

Shares of AXGN opened at $18.62 on Wednesday. The stock’s 50-day moving average price is $17.79 and its 200 day moving average price is $15.17. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $825.69 million, a price-to-earnings ratio of -58.19 and a beta of 1.00. AxoGen, Inc. has a 12-month low of $5.55 and a 12-month high of $21.00.

Analyst Ratings Changes

Separately, Canaccord Genuity Group boosted their target price on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.